CA
NBIX icon

Calton & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Calton & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,220
Closed -$235K – 287
2022
Q3 		$235K Sell
2,220
-53
-2% -$5.38K 0.13% 170
2022
Q2 		$221K Sell
2,273
-119
-5% -$11K 0.12% 198
2022
Q1 		$224K Buy
+2,392
New +$203K 0.07% 311
2021
Q4 		– Sell
-2,263
Closed -$217K – 397
2021
Q3 		$217K Sell
2,263
-18
-0.8% -$1.7K 0.05% 361
2021
Q2 		$222K Sell
2,281
-70
-3% -$6.71K 0.04% 363
2021
Q1 		$229K Sell
2,351
-1
-0% -$105 0.04% 348
2020
Q4 		$225K Buy
+2,352
New +$227K 0.04% 343
2020
Q3 		– Sell
-1,875
Closed -$229K – 363
2020
Q2 		$229K Buy
+1,875
New +$207K 0.05% 271
2020
Q1 		– Sell
-1,995
Closed -$215K – 355
2019
Q4 		$215K Buy
+1,995
New +$209K 0.04% 326

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Calton & Associates's NBIX Position: Q4 2022 in Review

Calton & Associates sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 2,220 shares — an estimated $235K sold.

Calton & Associates first reported a position in NBIX in Q4 2019 and held it in 9 quarters. The position peaked at $235K in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Calton & Associates reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Calton & Associates sold 2,220 Neurocrine Biosciences shares in Q4 2022, an estimated $235K.
  • Calton & Associates first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 9 quarters.
  • Calton & Associates's Neurocrine Biosciences position peaked at $235K in Q3 2022.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Calton & Associates's 13F filing for Q4 2022, filed 18 Jan 2023.